Protalix BioTherapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Protalix BioTherapeutics, Inc.
Servier is trying again with Tibsovo in the EU, while Protalix is using June 2021 data to support its filing for pegunigalsidase, which the US regulator turned down last April.
COVID does not appear to be a driving factor, and letters are split almost equally between clinical and quality concerns.
The US biotech has presented interesting preliminary data from the first four patients treated in the Phase I/II STAAR study evaluating isaralgagene civaparvovec for Fabry.
- Large Molecule
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Protalix Ltd.